[SMLE] Efficacy of durvalumab plus chemotherapy in small-cell lung cancer with Lambert-Eaton myasthenic syndrome
Posté : 20 févr. 2024 12:00
Respir Med Case Rep. 2023 Dec 23;47:101974. doi: 10.1016/j.rmcr.2023.101974. eCollection 2024.
ABSTRACT
Lambert-Eaton myasthenic syndrome (LEMS) is a rare disease but is often associated with small-cell lung cancer (SCLC). We discuss the case of a 65-year-old man diagnosed with SCLC-LEMS and treated with carboplatin, etoposide, and durvalumab. Lower extremity weakness and high anti-P/Q voltage-gated calcium channel (VGCC) antibody levels were diagnostic and helpful. The patient showed a reduction in neurological symptoms with treatment for SCLC, including an immune checkpoint inhibitor (ICI), without standard treatment for LEMS. This treatment may be a treatment option, although the recurrence of LEMS as an immune-related adverse events (irAEs) should be noted.
PMID:38374927 | PMC:PMC10874974 | DOI:10.1016/j.rmcr.2023.101974
Source: https://pubmed.ncbi.nlm.nih.gov/3837492 ... 1&v=2.18.0